The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Sequoia trial: Which subset of patients with CLL/SLL benefits the most from zanubritinib treatment?
Featured:
Constantine TamDuring the 61st American Society of Hematology (ASH) meeting in Orlando, US, the Lymphoma Hub was pleased to speak to Constantine Tam, Peter MacCallum Cancer Centre, Melbourne, AU. We asked about the results of the Sequoia trial and which subset of patients with CLL/SLL benefits the most from zanubritinib treatment?
Constantine Tam discusses the results of the trial investigating efficacy and safety of zanubrutinib, a small molecule BTK inhibitor, in patients with 17p deletion CLL, unsuitable for chemotherapy.
Sequoia trial: Which subset of patients with CLL/SLL benefits the most from zanubritinib treatment?